TY - JOUR
T1 - End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19
AU - Pebody, Richard G.
AU - Whitaker, Heather
AU - Ellis, Joanna
AU - Andrews, Nick
AU - Marques, Diogo F.P.
AU - Cottrell, Simon
AU - Reynolds, Arlene J.
AU - Gunson, Rory
AU - Thompson, Catherine
AU - Galiano, Monica
AU - Lackenby, Angie
AU - Robertson, Chris
AU - O'Doherty, Mark G.
AU - Owens, Katie
AU - Yonova, Ivelina
AU - Shepherd, Samantha J.
AU - Moore, Catherine
AU - Johnston, Jillian
AU - Donati, Matthew
AU - McMenamin, Jim
AU - Lusignan, Simon de
AU - Zambon, Maria
PY - 2019/11/1
Y1 - 2019/11/1
N2 - 2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation. End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: −3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: −13.7, 77.9) for all those ≥ 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2–17 year olds receiving LAIV was 48.6% (95% CI: −4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over.
AB - 2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation. End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: −3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: −13.7, 77.9) for all those ≥ 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2–17 year olds receiving LAIV was 48.6% (95% CI: −4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over.
KW - effectiveness
KW - influenza
KW - primary care
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85074525422&partnerID=8YFLogxK
UR - https://www.sciencedirect.com/journal/vaccine
U2 - 10.1016/j.vaccine.2019.10.071
DO - 10.1016/j.vaccine.2019.10.071
M3 - Article
C2 - 31685296
AN - SCOPUS:85074525422
SN - 0264-410X
JO - Vaccine
JF - Vaccine
ER -